Stramsen Biotech Seeks FDA Approval to Skip Phase 1 Trials for Plant-Based Wound Care Drug SBX1977
核心洞察
Stramsen Biotech (搜索) has submitted a Pre-IND package to the FDA for SBX1977, a novel topical plant-based drug candidate designed to treat acute and chronic wounds, including diabetic wounds.
The company is requesting to bypass Phase 1 trials and advance directly to Phase 2 based on extensive historical human use and robust preclinical safety data.
The FDA has scheduled a Pre-IND meeting for September 16, 2025, to review the comprehensive preclinical data package and clinical development strategy.
Stramsen Biotech (搜索) Inc. has submitted a comprehensive Pre-Investigational New Drug (Pre-IND) package to the U.S. Food and Drug Administration for SBX1977, a novel plant-based wound care medicine, with the ambitious goal of bypassing Phase 1 trials entirely. The Houston-based venture-backed biotechnology company announced on August 28, 2025, that the FDA has acknowledged their submission and scheduled a Pre-IND meeting for September 16, 2025.
Novel Plant-Based Approach to Wound Healing
SBX1977 represents a carefully formulated, standardized gel containing bioactive phytochemicals with powerful antimicrobial and wound-regenerative properties. The drug candidate is engineered to treat both acute and chronic wounds, including the most challenging chronic diabetic wounds. The unique composition is rooted in traditional medicine, with the plant material historically applied topically in gel form to treat wounds and skin infections.
Rigorous preclinical studies have confirmed the product's potent antimicrobial activity and demonstrated its remarkable ability to stimulate cell proliferation and tissue regeneration, while maintaining an exemplary safety profile in animal models.
Strategic Regulatory Pathway
Stramsen's strategy leverages extensive historical human use data combined with robust preclinical evidence to potentially advance directly to Phase 2 trials. This innovative regulatory approach could dramatically expedite the development process, bringing the therapy to patients more quickly than traditional development pathways.
"The wealth of existing safety and efficacy evidence for SBX1977 presents a compelling case for potentially waiving a separate Phase 1 trial. FDA concurrence with our assessment would enable us to advance directly to Phase 2," said Dr. Kefas Mugittu Ph.D, Co-CEO of Stramsen.
Company Pipeline and Development Focus
Stramsen Biotech (搜索) positions itself as a plant-based biotechnology company with advanced wound healing solutions, maintaining a pipeline of 33 total drug candidates for both infectious and noninfectious diseases. The Pre-IND package outlines an ambitious clinical development strategy specifically for SBX1977, marking a pivotal step toward upcoming clinical trials.
The comprehensive Pre-IND package contains all essential preclinical data required for IND approval, demonstrating the company's commitment to addressing critical healthcare needs in wound care management. The upcoming FDA meeting will be crucial in determining whether the agency agrees with Stramsen's assessment that Phase 1 trials can be bypassed based on the existing safety and efficacy evidence.